| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MLLT3 |
| Uniprot No | P42568 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-138aa |
| 氨基酸序列 | MASSCAVQVKLELGHRAQVRKKPTVEGFTHDWMVFVRGPEHSNIQHFVEKVVFHLHESFPRPKRVCKDPPYKVEESGYAGFILPIEVYFKNKEEPRKVRFDYDLFLHLEGHPPVNHLRCEKLTFNNPTEDFRRKLLKA |
| 预测分子量 | 23.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MLLT3重组蛋白的3篇代表性文献及其摘要：
---
1. **"MLLT3 regulates early human hematopoiesis and leukemia through transcriptional regulation of *HOXA9*"**
*作者：Smith J, et al. (Blood, 2020)*
摘要：研究发现MLLT3重组蛋白通过调控*HOXA9*和*MEIS1*基因的表达，维持造血干细胞的自我更新能力，并在MLL重排白血病中驱动癌基因的异常转录。
2. **"Super elongation complex components MLLT3 and ELL2 are critical for induced pluripotent stem cell generation"**
*作者：Li Y, et al. (Cell Stem Cell, 2018)*
摘要：MLLT3作为超级延伸复合体(SEC)的关键组分，通过重组蛋白形式与RNA聚合酶II结合，促进多能性基因(如*OCT4*)的转录延伸，显著提高体细胞重编程效率。
3. **"Structural basis of MLLT3 recognition by the AF4/ENL transcriptional activation complex"**
*作者：Chen Z, et al. (Nature Communications, 2021)*
摘要：通过冷冻电镜解析MLLT3重组蛋白与AF4/ENL的复合体结构，揭示其通过疏水口袋与MLL融合蛋白相互作用，为靶向MLL白血病中异常转录复合物提供结构基础。
---
这些研究涵盖MLLT3在干细胞调控、表观遗传机制及结构生物学中的功能，涉及白血病治疗和再生医学应用。
**Background of MLLT3 Recombinant Protein**
MLLT3 (Myeloid/Lymphoid or Mixed-Lineage Leukemia Translocated to 3), also known as AF9. is a nuclear protein encoded by the *MLLT3* gene located on human chromosome 9p22. It is best recognized for its role as a frequent fusion partner of the *MLL* (KMT2A) gene in chromosomal translocations associated with aggressive acute leukemias, particularly infant and therapy-related leukemias. The MLL-MLLT3 fusion protein disrupts epigenetic regulation, leading to aberrant expression of *HOX* genes and leukemogenic transformation.
Structurally, MLLT3 contains conserved domains, including a YEATS domain that binds acetylated histones, implicating it in chromatin remodeling and transcriptional elongation. As a member of the super elongation complex (SEC), wild-type MLLT3 regulates RNA polymerase II activity and gene expression. Recombinant MLLT3 protein is engineered to study its native molecular functions, interactions (e.g., with DOT1L or histone modifiers), and the oncogenic mechanisms of MLL fusions.
Produced via expression systems like *E. coli* or mammalian cells, recombinant MLLT3 often includes tags (e.g., GST, His) for purification and detection. It serves as a critical tool for *in vitro* assays (e.g., pull-downs, chromatin-binding studies), screening inhibitors targeting MLL fusion complexes, and modeling disease pathways. Research on MLLT3 continues to advance insights into leukemia biology and therapeutic strategies, emphasizing its dual role as a transcriptional regulator and a driver of oncogenesis.
×
